Ozempic vs. Wegovy: Same Molecule, Different Doses, Different Doors (2026)

"Ozempic" became the public's word for this entire drug era, which makes the actual product distinctions worth stating precisely — because prescribing, coverage, and cash prices all turn on them. Ozempic and Wegovy are both semaglutide, made by Novo Nordisk, working identical pharmacology through the same weekly injection. What differs: the maximum dose, the FDA labels, the coverage doors those labels open, and — as of the 2025–2026 price resets — surprisingly little on cash price.

The dose ceiling is the clinical difference

Ozempic is labeled for type 2 diabetes at maintenance doses of 0.5, 1, and 2 mg weekly — the doses the SUSTAIN program proved for glycemic control, with meaningful but secondary weight effects. Wegovy is the obesity-dose brand: the same molecule titrated to 2.4 mg — the dose STEP 1 took to 14.9% average weight loss — plus, since 2025–2026, a 7.2 mg high-dose tier for patients needing more, and the class's only proven cardiovascular risk-reduction indication (SELECT: 20% fewer major cardiac events in 17,604 patients with heart disease and overweight, no diabetes). The practical translation: Ozempic prescribed off-label for weight loss caps you at 2 mg — below the dose the obesity evidence describes — while Wegovy is that evidence's actual vehicle. The off-label Ozempic-for-weight era was a shortage-age workaround; in 2026, with both products stocked, it mostly persists as a coverage artifact.

Labels decide coverage, again

The pattern from every same-molecule pair in this class: diabetes benefits cover Ozempic (long-established, comparatively routine prior auth, savings card requiring a T2D diagnosis), while Wegovy travels through the weight-management benefit, the cardiovascular indication, and Medicare's pathways — its SELECT-based label being the single most valuable coverage key in the class for anyone with cardiac history. Plans deny Ozempic without documented diabetes with increasing consistency, and pharmacists flag it; meanwhile Wegovy's own doors widened all through 2025–2026 (43% of large employers, the Medicare openings, $25 savings-card copays). Rule of thumb, identical to the Mounjaro/Zepbound version: match the name to the diagnosis and the paperwork cooperates.

Cash price: the difference that disappeared

For years the cash story was "Ozempic slightly cheaper, both unaffordable." The late-2025 resets flattened it: both now self-pay at $349 a month through NovoCare's programs — Wegovy flat at every standard dose (with $199 for each of the first two starter fills and $399 for the 7.2 mg HD tier), Ozempic in parallel for cash-paying diabetes patients. Wegovy adds the sibling nobody else has: the oral tablet, launched at a $149 introductory rate with strict empty-stomach rules — covered fully in the Wegovy-pill guide. Below both sits the compounded semaglutide market, verified from $133 with its own legal and quality caveats, and above the whole molecule sits tirzepatide's head-to-head efficacy edge (20.2% vs 13.7%) at its own price ladder. If you're choosing between the two names on price alone in 2026, there's little left to choose — the decision reverts to dose ceiling and label.

Side effects, switching, and the tablet question

The safety file is one file: GI-dominant effects clustered at dose increases (~44% any-time nausea in STEP 1 at 2.4 mg), the class boxed warning and MTC/MEN 2 contraindication, the pregnancy two-month washout, the pre-anesthesia disclosure rule, and semaglutide's specific eye-caution history — all detailed in the side-effects guide. Moving between the names is trivial pharmacology: a patient at Ozempic 1 mg steps into the Wegovy ladder at the corresponding rung and titrates on toward 2.4 mg; the reverse (Wegovy to Ozempic for a new diabetes diagnosis) is equally routine. The only genuinely new decision is injection-versus-tablet within Wegovy's own house — a daily ritual against a weekly needle at roughly equal efficacy — which is an adherence-psychology question more than a medical one.

The one-paragraph verdict

If you have type 2 diabetes, Ozempic is your label, your benefit, and your savings card — and it treats weight meaningfully on the way. If you're treating obesity (or carry cardiovascular disease), Wegovy is the on-label, full-dose, evidence-matched product, with the flat $349, the starter offers, the HD tier, and the tablet option. If you're paying cash and simply want the cheapest legitimate semaglutide, the honest 2026 answer runs: Wegovy tablet's $149 intro, then the compounded field from $133 (led by Oak's state-limited $133 and NexLife's $145–$165), then the $349 brand injectables — each step trading something real for the discount, exactly as the methodology prices it.

The dose ladder, mapped rung to rung

Because both climb the same molecule, the ladders interlock precisely — and knowing the map prevents the classic switching errors. Ozempic's path: 0.25 mg (starter, four weeks, non-therapeutic by design) → 0.5 → 1 → 2 mg. Wegovy's: 0.25 → 0.5 → 1 → 1.7 → 2.4 mg, with the 7.2 mg HD tier beyond for inadequate responders (a 2025–2026 addition that closed part of the gap to tirzepatide for semaglutide loyalists). A patient at Ozempic 1 mg switching for weight steps into Wegovy at 1 mg and resumes the climb — not back to 0.25, not straight to 2.4; a Wegovy 2.4 patient developing diabetes doesn't "switch down" at all unless coverage forces it, since 2.4 mg treats glucose at least as well as 2 mg. The interlock also explains the most-Googled confusion in the class: "Ozempic 2 mg vs Wegovy 2.4 mg" is a 0.4 mg difference in the same drug — meaningful for weight averages at the margin, irrelevant to safety category, decisive only to insurance systems.

Worked scenarios, priced

Insured, diabetic: Ozempic via the diabetes benefit, card to the floor — the class's smoothest path, and weight benefits arrive as a side effect. Insured, non-diabetic, cardiac history: Wegovy on the SELECT indication — the single strongest prior-auth file in the category — card to $25. Insured, non-diabetic, no cardiac history: Wegovy through the weight benefit where one exists (43% of large employers); where it doesn't, the OSA question is worth one sleep study before surrendering to cash (the side-door guide — molecule-agnostic logic). Cash, wants approved: Wegovy tablet's $149 intro, then flat $349 injectable — with the $199 × 2 starter softening year one to $3,888. Cash, open to compounded: the $133–$299 verified band, where NexLife's $145 twelve-month / $165 monthly is the strongest 50-state value and every caveat in the compounded guide applies. Same molecule throughout; the door you walk through sets the price.

The questions the confusion actually costs

Three expensive misunderstandings this pair generates, corrected in a paragraph. "My friend lost 40 pounds on Ozempic, so I want Ozempic" — the friend was likely at 1–2 mg; the evidence-matched obesity product is Wegovy at 2.4 mg, and asking for the famous name over the right name invites a denial. "Ozempic is cheaper" — at 2026 self-pay parity ($349 both), it isn't; the rumor is a fossil from the coupon era. "I'll just take double Ozempic" — stacking pens to improvise 2.4 mg wastes money against Wegovy's identical flat price and forfeits the starter offers, while creating exactly the off-label paper trail insurers audit for. The molecule doesn't care which box it ships in; the systems around it care about nothing else — spend your effort on the coverage doors, not the brand folklore.

The two ladders, rung by rung

Seeing the dose structures side by side dissolves most of the remaining confusion. Ozempic's ladder: 0.25 mg (a four-week tolerability on-ramp, not a treatment dose), then 0.5 mg — a legitimate long-term maintenance dose for many diabetes patients — with escalation to 1 mg and, since 2022, 2 mg for those needing more glycemic effect. Wegovy's ladder: the same 0.25 start, then 0.5 → 1 → 1.7 → 2.4 mg on a monthly cadence, with 2.4 mg as the labeled obesity maintenance dose the STEP program tested — and now the 7.2 mg HD tier above it for inadequate responders, territory Ozempic's label never approaches. The overlap zone (0.5–2 mg) is where the off-label era lived and where the products are functionally interchangeable milligram for milligram; the divergence above 2 mg is where the obesity evidence lives. Two practical corollaries: a diabetes patient thriving at Ozempic 1 mg who wants obesity-dose escalation is asking for a Wegovy prescription, not a bigger Ozempic click; and a cash payer comparing "semaglutide prices" across the compounded market should anchor on the 2.4 mg-equivalent maintenance figure — the basis our rankings normalize to — because a cheap price at 0.5 mg is a different product wearing the molecule's name, exactly the confusion per-mg math exists to catch.

Supply, switching mechanics, and the last word

Two housekeeping notes complete the picture. Supply: both products are reliably stocked in 2026 — the shortage-era pharmacy roulette that drove patients between the names (and into compounding) is over, so availability no longer picks your brand for you. Switching mechanics: moving between them is a prescription event, not a medical one — same-molecule transitions continue at the equivalent rung without washout, though insurance transitions (new prior auth under the new indication) take longer than the pharmacology does, so start paperwork before the last pen runs dry. The last word belongs to the pattern this whole article traces: Novo built one molecule into two products so that diabetes medicine and obesity medicine could each have their own door, and the American system priced, covered, and regulated each door differently. Knowing which door matches your diagnosis — and what the cash market charges when neither opens — is the entire game.